AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2181565 — intervention group
Group type: EXPERIMENTAL
Intervention: low salt diet (5 g of salt/day), nifedipine and a salt supplement (6 g/day)
Number of subjects: 15
Study 2181565 — intervention group
Group type: COMPARATOR
Intervention: unrestricted diet and nifedipine (40 mg/day)
Number of subjects: 15
Study 2181565 — intervention group
Group type: COMPARATOR
Intervention: unrestricted diet and medication
Number of subjects: 15
Study 2181565 — intervention group
Group type: EXPERIMENTAL
Intervention: low salt diet (5 g of salt/day)
Number of subjects: 15
Study 340334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine therapy
Number of subjects: 22
Study 340334 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 22
Study 31914834 — intervention group
Group type: EXPERIMENTAL
Intervention: 40g low-fat milk powder + 63mg daidzein (daidzein group)
Number of subjects: 270
Study 31914834 — intervention group
Group type: COMPARATOR
Intervention: 40g low-fat milk powder (placebo group)
Number of subjects: 270
Study 30548230 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 164
Study 30548230 — intervention group
Group type: COMPARATOR
Intervention: Usual psychosocial care (UPC)
Number of subjects: 164
Study 28418102 — intervention group
Group type: EXPERIMENTAL
Intervention: solifenacin 5 mg + mirabegron 25 mg (combined S5 + M25 group)
Number of subjects: 0
Study 28418102 — intervention group
Group type: EXPERIMENTAL
Intervention: solifenacin 5 mg + mirabegron 50 mg (combined S5 + M50 group)
Number of subjects: 0
Study 28418102 — intervention group
Group type: COMPARATOR
Intervention: solifenacin 5 mg
Number of subjects: 0
Study 28418102 — intervention group
Group type: COMPARATOR
Intervention: mirabegron 25 mg
Number of subjects: 0
Study 28418102 — intervention group
Group type: COMPARATOR
Intervention: mirabegron 50 mg
Number of subjects: 0
Study 25535020 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific guides
Number of subjects: 70
Study 25535020 — intervention group
Group type: COMPARATOR
Intervention: Standard instrumentation
Number of subjects: 70
Study 22782923 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to full-text articles
Number of subjects: 77
Study 22782923 — intervention group
Group type: COMPARATOR
Intervention: Access to abstracts-only
Number of subjects: 77
Study 21094194 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating rate of foods (g/min)
Number of subjects: 37
Study 21094194 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating rate
Number of subjects: 37
Study 18677657 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus 1% cream
Number of subjects: 48
Study 18677657 — intervention group
Group type: COMPARATOR
Intervention: Topical ketoconazole 2% cream
Number of subjects: 48
Study 17557047 — intervention group
Group type: EXPERIMENTAL
Intervention: Various endoscopic therapies for GERD
Number of subjects: 0
Study 17557047 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic techniques
Number of subjects: 0
Study 17557047 — intervention group
Group type: COMPARATOR
Intervention: Medical and laparoscopic management of GERD
Number of subjects: 0
Study 15286958 — intervention group
Group type: EXPERIMENTAL
Intervention: SS (supplements both before and after surgery)
Number of subjects: 152
Study 15286958 — intervention group
Group type: EXPERIMENTAL
Intervention: CS (postoperative supplements only)
Number of subjects: 152
Study 15286958 — intervention group
Group type: COMPARATOR
Intervention: CC (no nutritional supplements)
Number of subjects: 152
Study 15286958 — intervention group
Group type: EXPERIMENTAL
Intervention: SC (supplements only before surgery)
Number of subjects: 152
Study 11150359 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.15 mg/kg/day for 3 days, followed by tapering over 7 days)
Number of subjects: 220
Study 11150359 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 220
Study 11150359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 9744982 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive Pill (OCP)
Number of subjects: 3996
Study 9744982 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 3996
Study 7877205 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg orally)
Number of subjects: 38
Study 7877205 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (20 mg orally)
Number of subjects: 38
Study 7877205 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with nadolol and isosorbide‐5‐mononitrate
Number of subjects: 38
Study 7877205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 7877205 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg orally) followed by isosorbide‐5‐mononitrate
Number of subjects: 38
Study 3411740 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 147
Study 3411740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 4895340 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Number of subjects: 1257
Study 4895340 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroethylene
Number of subjects: 1257
Study 4895340 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen
Number of subjects: 1257
Study 31200686 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mindfulness-based intervention (MBI)
Number of subjects: 19
Study 31200686 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting period)
Number of subjects: 19
Study 28521751 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated psychological and advocacy intervention (Nguvu) with usual care
Number of subjects: 400
Study 28521751 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 400
Study 26364276 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine
Number of subjects: 40
Study 26364276 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine
Number of subjects: 40
Study 26364276 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 40
Study 24267039 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA ground beef
Number of subjects: 17
Study 24267039 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-MUFA ground beef
Number of subjects: 17
Study 24267039 — intervention group
Group type: EXPERIMENTAL
Intervention: Single exercise session after washout
Number of subjects: 17
Study 24267039 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise after low-MUFA ground beef diet
Number of subjects: 17
Study 24267039 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise after high-MUFA ground beef intervention
Number of subjects: 17
Study 24267039 — intervention group
Group type: COMPARATOR
Intervention: Exercise and high-MUFA diet
Number of subjects: 17
Study 21962806 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 6
Study 21962806 — intervention group
Group type: COMPARATOR
Intervention: No iron supplementation
Number of subjects: 6
Study 18815569 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 60) performed the flamingo balance test with two additional trials every 3 days.
Number of subjects: 130
Study 18815569 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 70) performed the flamingo balance test without additional trials.
Number of subjects: 130
Study 18815569 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups underwent a retention trial 1 week later after the final trial.
Number of subjects: 130
Study 16683434 — intervention group
Group type: EXPERIMENTAL
Intervention: Solis fixation
Number of subjects: 104
Study 16683434 — intervention group
Group type: COMPARATOR
Intervention: Titanium plate fixation
Number of subjects: 104
Study 14594148 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral methadone (5 mg bd)
Number of subjects: 18
Study 14594148 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral methadone (10 mg bd)
Number of subjects: 18
Study 10885044 — intervention group
Group type: EXPERIMENTAL
Intervention: Free treatment (90 days of substance abuse treatment)
Number of subjects: 362
Study 10885044 — intervention group
Group type: EXPERIMENTAL
Intervention: Free treatment
Number of subjects: 362
Study 10885044 — intervention group
Group type: COMPARATOR
Intervention: Paid treatment
Number of subjects: 362
Study 9374236 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea 3.6 g per day
Number of subjects: 28
Study 9374236 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea 5.4 g per day
Number of subjects: 28
Study 9374236 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 28
Study 1565485 — intervention group
Group type: EXPERIMENTAL
Intervention: Head tilted contralateral to the side of lesion
Number of subjects: 48
Study 1565485 — intervention group
Group type: EXPERIMENTAL
Intervention: Head extension
Number of subjects: 48
Study 1565485 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 48
Study 2989571 — intervention group
Group type: COMPARATOR
Intervention: Ensure (0 g/day soy fiber)
Number of subjects: 16
Study 2989571 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrich (30 g/day soy fiber)
Number of subjects: 16
Study 2989571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure with 30 g/day soy fiber (diet c)
Number of subjects: 16
Study 2989571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure with 60 g/day soy fiber (diet d)
Number of subjects: 16
Study 2989571 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐selected diet
Number of subjects: 16
Study 2989571 — intervention group
Group type: EXPERIMENTAL
Intervention: All fiber-containing diets
Number of subjects: 16
Study 2989571 — intervention group
Group type: COMPARATOR
Intervention: Ensure diet
Number of subjects: 16
Study 2989571 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-supplemented diets and self‐selected diet
Number of subjects: 16
Study 30799392 — intervention group
Group type: EXPERIMENTAL
Intervention: OPF-108 (revised formula)
Number of subjects: 110
Study 30799392 — intervention group
Group type: COMPARATOR
Intervention: ELN (previous formula)
Number of subjects: 110
Study 30799392 — intervention group
Group type: COMPARATOR
Intervention: OPF-108 and ELN
Number of subjects: 110
Study 30045764 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISP tool intervention
Number of subjects: 732
Study 30045764 — intervention group
Group type: COMPARATOR
Intervention: Standardised information on cancer prevention (Control)
Number of subjects: 732
Study 26325248 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use surgical instruments (SteriSpine™ PS Pedicle Screw System)
Number of subjects: 49
Study 26325248 — intervention group
Group type: COMPARATOR
Intervention: Reusable instrumentation (older series)
Number of subjects: 49
Study 24485347 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 450
Study 24485347 — intervention group
Group type: COMPARATOR
Intervention: Individual Therapy (IP)
Number of subjects: 450
Study 22019281 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drink containing 10(10)CFU/d Lactobacillus paracasei (LPC37) + Calcium phosphate (CaP; 1g Ca/d)
Number of subjects: 32
Study 22019281 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drink containing 10(10)CFU/d Lactobacillus paracasei (LPC37)
Number of subjects: 32
Study 22019281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (bread without CaP)
Number of subjects: 32
Study 20849215 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral deep brain stimulation (DBS) to the subthalamic nucleus or globus pallidus internus (GPi)
Number of subjects: 52
Study 20849215 — intervention group
Group type: COMPARATOR
Intervention: Bilateral deep brain stimulation (DBS)
Number of subjects: 52
Study 20849215 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral DBS
Number of subjects: 52
Study 20849215 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline asymmetry
Number of subjects: 52
Study 20849215 — intervention group
Group type: COMPARATOR
Intervention: GPi DBS
Number of subjects: 52
Study 17996819 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aortic flow augmentation using the Orqis Medical Cancion System (up to 1.5 L/min)
Number of subjects: 0
Study 17996819 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 0
Study 17996819 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aortic flow augmentation
Number of subjects: 0
Study 16029228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobra Perilaryngeal Airway
Number of subjects: 29
Study 16029228 — intervention group
Group type: COMPARATOR
Intervention: Classic Laryngeal Mask Airway
Number of subjects: 29
Study 12297350 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillator with a rhythm display
Number of subjects: 60
Study 12297350 — intervention group
Group type: COMPARATOR
Intervention: Defibrillator without a rhythm display
Number of subjects: 60
Study 10356077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary folate group (high in vegetables and citrus fruit, approximately 560 micrograms of folate)
Number of subjects: 66
Study 10356077 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid group (low in folate, approximately 210 micrograms of folate plus 250 micrograms of folic acid daily)
Number of subjects: 66
Study 10356077 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (same low-folate diet as the folic acid group plus placebo tablet)
Number of subjects: 66
Study 8595287 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine antenatal care by general practitioners and midwives
Number of subjects: 1765
Study 1673133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol (15 mg)
Number of subjects: 65
Study 1673133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 7471621 — intervention group
Group type: EXPERIMENTAL
Intervention: Methapyrilene 20 mg intravenously
Number of subjects: 8
Study 7471621 — intervention group
Group type: EXPERIMENTAL
Intervention: Methapyrilene 50 mg orally
Number of subjects: 8
Study 7471621 — intervention group
Group type: EXPERIMENTAL
Intervention: Methapyrilene 25 mg orally
Number of subjects: 8
Study 7471621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31300183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health advisor intervention (one-on-one teaching course)
Number of subjects: 347
Study 31300183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health advisor intervention
Number of subjects: 347
Study 31300183 — intervention group
Group type: COMPARATOR
Intervention: Control group (leaflet only)
Number of subjects: 347
Study 28666360 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control (CLC)
Number of subjects: 44
Study 26212349 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pain
Number of subjects: 638
Study 26212349 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute postoperative pain-at-rest
Number of subjects: 638
Study 26212349 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute postoperative pain-on-movement
Number of subjects: 638
Study 26212349 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain-at-rest after THR
Number of subjects: 638
Study 26212349 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain-on-movement after TKR
Number of subjects: 638
Study 24393328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (16-16-12-12-8-4 mg/d)
Number of subjects: 820
Study 24393328 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 820
Study 23032160 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap-IPV (REPEVAX®)
Number of subjects: 456
Study 23032160 — intervention group
Group type: COMPARATOR
Intervention: Tetanus monovalent vaccine (TMV; Vaccin Tétanique Pasteur® or Tetavax®)
Number of subjects: 456
Study 23032160 — intervention group
Group type: COMPARATOR
Intervention: Tetanus monovalent vaccine (TMV)
Number of subjects: 456
Study 19653742 — intervention group
Group type: EXPERIMENTAL
Intervention: Redundant targets (target-target displays)
Number of subjects: 0
Study 19653742 — intervention group
Group type: COMPARATOR
Intervention: Single target (target-distractor displays)
Number of subjects: 0
Study 19653742 — intervention group
Group type: COMPARATOR
Intervention: No targets (distractor-distractor displays)
Number of subjects: 0
Study 17457706 — intervention group
Group type: COMPARATOR
Intervention: ia 20 ml of 0.25 % bupivacaine at the end of the operation
Number of subjects: 60
Study 17457706 — intervention group
Group type: EXPERIMENTAL
Intervention: ia 20 ml of 0.25 % bupivacaine and 100 mg of tramadol at the end of the operation
Number of subjects: 60
Study 17457706 — intervention group
Group type: EXPERIMENTAL
Intervention: ia 100 mg of tramadol diluted in 20 ml of saline solution 30 minutes before skin incision and 20 ml of 0.25% bupivacaine at the end of the operation
Number of subjects: 60
Study 17457706 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive ia tramadol
Number of subjects: 60
Study 15243746 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (started at 0900 hours after monitored sleep)
Number of subjects: 29
Study 15243746 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (started 12 hours later)
Number of subjects: 29
Study 12152362 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of alternatives and disablers
Number of subjects: 0
Study 12152362 — intervention group
Group type: EXPERIMENTAL
Intervention: Speaker control
Number of subjects: 0
Study 12152362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic type
Number of subjects: 0
Study 9615981 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 500 impulses of low‐energetic extracorporal shock‐wave therapy
Number of subjects: 50
Study 9615981 — intervention group
Group type: COMPARATOR
Intervention: 3 x 100 impulses of low‐energetic extracorporal shock‐wave therapy
Number of subjects: 50
Study 7657008 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose infusion
Number of subjects: 100
Study 7657008 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 100
Study 2529521 — intervention group
Group type: EXPERIMENTAL
Intervention: human antiserum to lipopolysaccharide (LPS)
Number of subjects: 60
Study 355810 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (100 international units per kilogram of body weight, subcutaneously every eight hours for two weeks)
Number of subjects: 50
Study 355810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31994374 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke leaves and ginger root extracts combination (320 mg) + simethicone (40 mg)
Number of subjects: 50
Study 31618656 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy (RARC)
Number of subjects: 1781
Study 31618656 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 1781
Study 31618656 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hydronephrosis
Number of subjects: 1781
Study 31618656 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hospital volume
Number of subjects: 1781
Study 30058182 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial stimuli
Number of subjects: 145
Study 30058182 — intervention group
Group type: EXPERIMENTAL
Intervention: Textual stimuli
Number of subjects: 145
Study 30058182 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 145
Study 28703605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 85
Study 28703605 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT integrated with motivational interviewing (MI)
Number of subjects: 85
Study 28703605 — intervention group
Group type: COMPARATOR
Intervention: Control group (CBT)
Number of subjects: 85
Study 26401986 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (50,000 IU every 5 days for 3 months)
Number of subjects: 94
Study 26401986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 23611097 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous blood purification (CBP)
Number of subjects: 41
Study 23611097 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 21501872 — intervention group
Group type: EXPERIMENTAL
Intervention: Early recovery symptom management (SM) telehealth intervention delivered by Health Buddy for 6 weeks
Number of subjects: 232
Study 21501872 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 232
Study 20103833 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg/kg (group M)
Number of subjects: 45
Study 20103833 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 2 microg/kg (group C2)
Number of subjects: 45
Study 20103833 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 4 microg/kg (group C4)
Number of subjects: 45
Study 17543634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (30 mg/day)
Number of subjects: 240
Study 17543634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 17543634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 240
Study 15090634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 120 microg BID
Number of subjects: 498
Study 15090634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study 11773803 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum delivered by syringe
Number of subjects: 60
Study 11773803 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum delivered on a pacifier
Number of subjects: 60
Study 11773803 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 60
Study 11773803 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 60
Study 11773803 — intervention group
Group type: COMPARATOR
Intervention: Colostrum via syringe
Number of subjects: 60
Study 9333953 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of intramedullary compression
Number of subjects: 203
Study 9333953 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (without avoidance of intramedullary compression)
Number of subjects: 203